The cholecystokinin antagonist proglumide has an analgesic effect when used alone in human neuropathic pain: a case report

The cognitive–evaluative (C–E) dimension of pain is commonly observed in patients with a relatively long duration of pain. However, little is known about the effects of pain relapse on the C–E dimension of pain. Moreover, the improvement process of the C–E dimension of pain following treatment is unknown. The objective of this case report was to (a) demonstrate that the C–E dimension was affected in the acute phase of neuropathic pain in cases of pain relapse, and (b) demonstrate the improvement process of the C–E dimension of pain. A woman was diagnosed with low back pain (LBP) and sciatica. The patient had previously experienced symptoms of LBP and sciatica; thus, this episode was a case of pain relapse. At the beginning of rehabilitation, the C–E dimension of pain was present in addition to the sensory–discriminative (S–D) dimension of pain. It was observed that improvement of the C–E dimension of pain was delayed in comparison with that of the S–D dimension of pain. The C–E dimension of pain was observed with pain relapse even though it was in the acute phase of pain. This case provides a novel insight into the C–E dimension of pain. Moreover, the delay in improving the C–E dimension of pain indicates a difference in the improvement process for each pain dimension.

Download Full-text

Neuropathic pain post-COVID-19: a case report

BMJ Case Reports ◽

10.1136/bcr-2021-243459 ◽

2021 ◽

Vol 14 (7) ◽

pp. e243459

Author(s):

Matthew McWilliam ◽

Michael Samuel ◽

Fadi Hasan Alkufri

Keyword(s):

Neuropathic Pain ◽

Case Report ◽

Hospital Admission ◽

Skin Biopsy ◽

Neurological Examination ◽

Autonomic Failure ◽

Whole Body ◽

Shortness Of Breath ◽

Burning Pain ◽

Electrophysiological Tests

A 61-year-old man with no significant medical history developed fever, headache and mild shortness of breath. He tested positive for SARS-CoV-2 and self-isolated at home, not requiring hospital admission. One week after testing positive, he developed acute severe burning pain affecting his whole body, subsequently localised distally in the limbs. There was no ataxia or autonomic failure. Neurological examination was unremarkable. Electrophysiological tests were unremarkable. Skin biopsy, lumbar puncture, enhanced MRI of the brachial plexus and MRI of the neuroaxis were normal. His pain was inadequately controlled with pregabalin but improved while on a weaning regimen of steroids. This case highlights the variety of possible symptoms associated with SARS-CoV-2 infection.

Download Full-text

Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report

Pain ◽

10.1016/0304-3959(91)90226-n ◽

1991 ◽

Vol 47 (3) ◽

pp. 341-344 ◽

Cited By ~ 24

Author(s):

Julio Pascual ◽

Julio Freijanes ◽

José Berciano ◽

Carlos Pesquera

Keyword(s):

Case Report ◽

Analgesic Effect ◽

Opioid Mechanisms

Download Full-text

The serotonin??3 receptor antagonist ondansetron may have an analgesic effect in patients with neuropathic pain,

Inpharma Weekly ◽

10.2165/00128413-200314160-00017 ◽

2003 ◽

Vol &NA; (1416) ◽

pp. 8

Author(s):

&NA;

Keyword(s):

Neuropathic Pain ◽

Receptor Antagonist ◽

Analgesic Effect

Download Full-text

The Analgesic Effect of Rolipram, a Phosphodiesterase 4 Inhibitor, on Chemotherapy-Induced Neuropathic Pain in Rats

Anesthesia & Analgesia ◽

10.1213/ane.0000000000000853 ◽

2015 ◽

Vol 121 (3) ◽

pp. 822-828 ◽

Cited By ~ 8

Author(s):

Hee Kee Kim ◽

Jae Young Kwon ◽

Changwon Yoo ◽

Salahadin Abdi

Keyword(s):

Neuropathic Pain ◽

Analgesic Effect ◽

Phosphodiesterase 4 ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Regional migratory osteoporosis: case report of a patient with neuropathic pain

Rheumatology International ◽

10.1007/s00296-009-1256-1 ◽

2009 ◽

Vol 31 (10) ◽

pp. 1375-1381 ◽

Cited By ~ 2

Author(s):

Esin Kartal ◽

Ebru Sahin ◽

Banu Dilek ◽

Meltem Baydar ◽

Metin Manisali ◽

...

Keyword(s):

Neuropathic Pain ◽

Case Report ◽

Regional Migratory Osteoporosis

Download Full-text

Pain Syndrome, Markers of Bone Metabolism in Patients with Osteoarthritis, Approaches to Drug Therapy and the Impact of Obesity

Family Medicine ◽

10.30841/2307-5112.5.2016.248640 ◽

2016 ◽

pp. 26-35

Author(s):

Oleksandr Kuryata ◽

Anna Cherkasova

Keyword(s):

Neuropathic Pain ◽

Bone Metabolism ◽

Clinical Efficacy ◽

Functional Ability ◽

Analgesic Effect ◽

Pain Syndrome ◽

Knee Joints ◽

Osteocalcin Level ◽

Positive Effects ◽

The Impact

The objective: to assess the nature of pain in patients with osteoarthritis, the impact of obesity on the clinical efficacy of treatment of osteoarthritis (OA) and dynamics of bone metabolism markers. Patients and methods. The research included 150 patients with OA, who were divided into two groups, according to the receiving therapy. Patients of the main group – received diacerein (drug «Flexirin» PC «Kyiv Vitamin Factory») and patients of control group – received only nonsteroidal anti1inflammatory drugs (NSAIDs). Results. The prevalence of neuropathic pain component in patients with OA was 64,7%, among which 80,7% use NSAIDs as an analgesic therapy. Obesity in patients with OA was associated with significantly higher levels of pain from the side of knee joints and higher degree of stiffness according to WOMAC index. The results of the study demonstrated a direct moderate correlation (R = 0,49; p = 0,04) between PICP level and the severity of pain at physical load from the side of hands and hip joints. The therapy by diacerein within 3 months resulted in a reliable decrease of pain syndrome intensity from the side of all articular zones, unlike to isolated NSAIDs use, where a reliable analgesic effect was demonstrated only from the side of knee joints. Obesity in patients with OA led to a significant decrease in clinical efficacy of therapy in point of functional status of the joints. Conclusions. Neuropathic pain is quite common among patients with OA, which at the same time is associated with the lack of patient’s awareness about possible risks during NSAID’s use. Medical treatment by diacerein (drug “Flexirin”) causes stability of osteocalcin level, in contrast to the isolated NSAIDs use, where priority changes have been demonstrated against osteocalcin level decrease. The use of diacerein also resulted to additional positive effects from the side of zonal prevalence of analgesic effect and improving of functional ability of joints. Obesity in patients with OA was associated with a reliable increase of pain level intensity from the side of knee joints and the higher degree of functional limitation, causing at the same time, reduction of clinical efficacy of therapy in point of achieving analgesic effect and improving functional ability of joints.

Download Full-text

Central Neuropathic Pain in a Patient with Multiple Sclerosis Treated Successfully with Topical Amitriptyline

Case Reports in Medicine ◽

10.1155/2012/471835 ◽

2012 ◽

Vol 2012 ◽

pp. 1-3 ◽

Cited By ~ 11

Author(s):

David J. Kopsky ◽

Remko Liebregts ◽

Jan M. Keppel Hesselink

Keyword(s):

Multiple Sclerosis ◽

Neuropathic Pain ◽

Adverse Events ◽

Active Compound ◽

Analgesic Effect ◽

Tricyclic Antidepressants ◽

Double Blind ◽

Carryover Effect ◽

Double Blind Placebo ◽

Central Neuropathic Pain

Central neuropathic pain in patients with multiple sclerosis (MS) is a common debilitating symptom, which is mostly treated with tricyclic antidepressants or antiepileptics. Unfortunately, the use of these drugs is often limited due to adverse events. We investigated the analgesic effect of topical amitriptyline 5% and 10% cream in a patient with central neuropathic pain due to MS. The analgesic effect of topical amitriptyline cream on neuropathic pain was dose related. To evaluate whether this analgesic effect is due to the active compound or placebo, we conducted a double-blind placebo-controlled n-of-1 study with amitriptyline 5% cream and placebo. The instruction was to alternate the creams every week following the pattern ABAB, with an escape possibility of amitriptyline 10% cream. The result was a complete pain reduction after application of cream B, while most of the time cream A did not reduce the pain. The patient could correctly unblind both creams, determining B as active. She noted that in the week of using the active cream no allodynia was present, with a carryover effect of one day.

Download Full-text